Enrique Grande, MD, MD Anderson Cancer Center Madrid, Madrid, Spain summarizes three abstracts in thyroid cancer presented at ESMO 2020. Firstly, a phase II study assessing the efficacy and safety of anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma (NCT02586337). This study supports the use of anlotinib as a new therapeutic option in these patients. The second study was a phase III study (NCT03048877) evaluating apatinib in patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer. In this study, apatinib significantly prolonged the progression free survival (PFS), overall survival (OS), and improved the objective response rate (ORR). The third study was the phase II, NRG-RTOG 0912 study, looking at radiation therpy and and paclitaxel with pazopanib or placebo in patients with anaplastic thyroid cancer. There was no statistically significant improvement in OS with pazopanib added to paclitaxel. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).